https://www.selleckchem.com/pr....oducts/ro-20-1724.ht
Background It is unknown to what extent the clinical benefits of PCI outweigh the risks and costs in patients with vs. without cancer and within each cancer type. We performed the first known nationally representative propensity score analysis of PCI mortality and cost among all eligible adult inpatients by cancer and its types. Methods This multicenter case-control study used machine learning-augmented propensity score-adjusted multivariable regression to assess the above outcomes and disparities using the 2016 nationally representa
Like
Comment
Share
